Department of Psychiatry, BIDMC, Harvard Medical School, Boston, Massachussetts 02215, United States.
ACS Chem Neurosci. 2021 Jan 6;12(1):42-48. doi: 10.1021/acschemneuro.0c00554. Epub 2020 Dec 18.
5-HT7 receptor antagonism has been shown to ameliorate ketamine-induced schizophrenia-like deficits in extradimensional set-shifting using the attentional set-shifting task (ASST). However, this rodent paradigm distinguishes between several types of cognitive rigidity associated with neuropsychiatric conditions. The goal of this study was to test 5-HT7 receptor involvement in the reversal learning component of the ASST because this ability depends primarily on the orbito-frontal cortex, which shows strong 5-HT7 receptor expression. We found that impaired performance on the ASST induced by NMDA receptor blockade (MK-801, 0.2 mg/kg) in 14 rats was reversed by coadministration of the 5-HT7 receptor antagonist SB-269970. The strongest effect was found on the reversal phases of ASST, whereas injection of SB-269970 alone had no effect. These results indicate that 5-HT7 receptor mechanisms may have a specific contribution to the complex cognitive deficits, increasing perseverative responding, in psychiatric diseases, including schizophrenia, depression, and anorexia nervosa, which express different forms of cognitive inflexibility.
5-HT7 受体拮抗作用已被证明可改善使用注意定势转换任务(ASST)改善氯胺酮诱导的精神分裂样的多维定势转换缺陷。然而,这种啮齿动物范式区分了几种与神经精神疾病相关的认知僵化类型。本研究的目的是测试 5-HT7 受体在 ASST 的反转学习成分中的参与,因为这种能力主要依赖于眶额皮层,眶额皮层显示出强烈的 5-HT7 受体表达。我们发现,在 14 只大鼠中,NMDA 受体阻断(MK-801,0.2mg/kg)诱导的 ASST 表现受损可通过共施用 5-HT7 受体拮抗剂 SB-269970 逆转。在 ASST 的反转阶段发现了最强的效果,而单独注射 SB-269970 则没有效果。这些结果表明,5-HT7 受体机制可能对包括精神分裂症、抑郁症和神经性厌食症在内的精神疾病的复杂认知缺陷有特定的贡献,这些疾病表现出不同形式的认知灵活性不足。